Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

HIV Infection

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 52 articles: HTML format

Single Articles

December 2024
1. LEE MJ, Yeon JH, Lee J, Kang YH, et al
   Senescence of endothelial cells increases susceptibility to Kaposi's sarcoma-associated herpesvirus infection via CD109-mediated viral entry.
   J Clin Invest. 2024 Dec 12:e183561. doi: 10.1172/JCI183561.
   PubMed     Abstract available
   
   
   November 2024
2. GONZALEZ-NAVARRO I, Urrea V, Galvez C, Garcia-Guerrero MDC, et al
   Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir.
   J Clin Invest. 2024 Nov 29:e183952. doi: 10.1172/JCI183952.
   PubMed     Abstract available
   
   
   October 2024
3. DURAND CM, Redd AD
   HOPE springs eternal: lack of HIV superinfection in HIV Organ Policy Equity Act kidney transplants.
   J Clin Invest. 2024;134:e184326.
   PubMed     Abstract available
   
   
   
4. MANNING MR, Blazkova J, Justement JS, Shi V, et al
   Timing of antiretroviral therapy initiation affects intact HIV reservoirs following analytical treatment interruption.
   J Clin Invest. 2024;134:e181632.
   PubMed    
   
   
   
5. KINCER LP, Dravid A, Trunfio M, Calcagno A, et al
   Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation.
   J Clin Invest. 2024;134:e176358.
   PubMed     Abstract available
   
   
   September 2024
6. MIHEALSICK E, Word A, Scully EP
   The impact of sex on HIV immunopathogenesis and therapeutic interventions.
   J Clin Invest. 2024;134:e180075.
   PubMed     Abstract available
   
   
   
7. TRAVIESO T, Stadtler H, Alavian N, Gao F, et al
   Longitudinal analysis of viral dynamics in HIV+ to HIV+ HOPE Act kidney-transplant recipients.
   J Clin Invest. 2024 Sep 10:e181560. doi: 10.1172/JCI181560.
   PubMed     Abstract available
   
   
   July 2024
8. KLOTMAN ME, Haynes BF
   The other pandemic: lessons from 40 years of HIV research.
   J Clin Invest. 2024;134:e183039.
   PubMed    
   
   
   June 2024
9. JOY J, Gervassi AL, Chen L, Kirshenbaum B, et al
   Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation.
   J Clin Invest. 2024 Jun 4:e159569. doi: 10.1172/JCI159569.
   PubMed     Abstract available
   
   
   May 2024
10. TEBAS P, Jadlowsky JK, Shaw PA, Tian L, et al
    CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
    J Clin Invest. 2024;134:e181576.
    PubMed    
    
    
    April 2024
11. WHITEHILL GD, Joy J, Marino FE, Krause RJ, et al
    Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1.
    J Clin Invest. 2024 Apr 23:e176673. doi: 10.1172/JCI176673.
    PubMed     Abstract available
    
    
    
12. EICHHOLZ K, Fukazawa Y, Peterson CW, Haeseleer F, et al
    Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers.
    J Clin Invest. 2024;134:e169309.
    PubMed     Abstract available
    
    
    March 2024
13. ELIZALDI SR, Hawes CE, Verma A, Shaan Lakshmanappa Y, et al
    Chronic SIV-induced neuroinflammation disrupts CCR7+CD4+ T cell immunosurveillance in the rhesus macaque brain.
    J Clin Invest. 2024 Mar 12:e175332. doi: 10.1172/JCI175332.
    PubMed     Abstract available
    
    
    February 2024
14. GASCA-CAPOTE C, Lian X, Gao C, Roseto IC, et al
    The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
    J Clin Invest. 2024 Feb 20:e174215. doi: 10.1172/JCI174215.
    PubMed     Abstract available
    
    
    January 2024
15. JONGO S, Church LWP, Milando F, Qassim M, et al
    Safety and protective efficacy of PfSPZ vaccine administered to HIV negative and positive Tanzanian adults.
    J Clin Invest. 2024 Jan 9:e169060. doi: 10.1172/JCI169060.
    PubMed     Abstract available
    
    
    
16. SHEN XY, Zhang J, Huang HZ, Li SD, et al
    Synapsin 2a/Synaptogyrin-3 interaction regulates fear extinction in mice.
    J Clin Invest. 2024 Jan 4:e172802. doi: 10.1172/JCI172802.
    PubMed     Abstract available
    
    
    September 2023
17. WIETGREFE SW, Anderson J, Duan L, Southern PJ, et al
    Initial productive and latent HIV infections originate in vivo by infection of resting T cells.
    J Clin Invest. 2023 Sep 21:e171501. doi: 10.1172/JCI171501.
    PubMed     Abstract available
    
    
    
18. DRAGONI F, Kwaa A, Traut CC, Veenhuis RT, et al
    Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1-infected T cell clones.
    J Clin Invest. 2023 Sep 12:e171097. doi: 10.1172/JCI171097.
    PubMed     Abstract available
    
    
    July 2023
19. MCMYN NF, Varriale J, Fray EJ, Zitzmann C, et al
    The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.
    J Clin Invest. 2023 Jul 18:e171554. doi: 10.1172/JCI171554.
    PubMed     Abstract available
    
    
    June 2023
20. BEKERMAN E, Yant SR, VanderVeen LA, Hansen D, et al
    Long-acting lenacapavir acts as an effective pre-exposure prophylaxis in a rectal SHIV challenge macaque model.
    J Clin Invest. 2023 Jun 29:e167818. doi: 10.1172/JCI167818.
    PubMed     Abstract available
    
    
    
21. TANG Y, Chaillon A, Gianella S, Wong LM, et al
    Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy.
    J Clin Invest. 2023;133:e167417.
    PubMed     Abstract available
    
    
    April 2023
22. PIERCE CA, Loh LN, Steach HR, Cheshenko N, et al
    HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal.
    J Clin Invest. 2023 Apr 20:e164317. doi: 10.1172/JCI164317.
    PubMed     Abstract available
    
    
    March 2023
23. EMERY A, Joseph SB, Swanstrom R
    Nonsuppressible viremia during HIV-1 therapy meets molecular virology.
    J Clin Invest. 2023;133:e167925.
    PubMed     Abstract available
    
    
    February 2023
24. COHEN KW, Fiore-Gartland A, Walsh SR, Yusim K, et al
    Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
    J Clin Invest. 2023;133:e163338.
    PubMed     Abstract available
    
    
    
25. KENNEDY BD, Blazkova J, Justement JS, Shi V, et al
    Comprehensive analysis of HIV reservoirs in elite controllers.
    J Clin Invest. 2023;133:e165446.
    PubMed    
    
    
    January 2023
26. PERDOMO-CELIS F, Passaes C, Monceaux V, Volant S, et al
    Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control.
    J Clin Invest. 2023;133:e167843.
    PubMed    
    
    
    
27. WHITE JA, Wu F, Yasin S, Moskovljevic M, et al
    Clonally expanded HIV-1 proviruses with 5'-Leader defects can give rise to nonsuppressible residual viremia.
    J Clin Invest. 2023 Jan 5:e165245. doi: 10.1172/JCI165245.
    PubMed     Abstract available
    
    
    December 2022
28. KIM JT, Zack JA
    A humanized mouse model to study NK cell biology during HIV infection.
    J Clin Invest. 2022;132:e165620.
    PubMed     Abstract available
    
    
    
29. PELUSO MJ, Deveau TM, Munter SE, Ryder DM, et al
    Impact of pre-existing chronic viral infection and reactivation on the development of long COVID.
    J Clin Invest. 2022 Dec 1:e163669. doi: 10.1172/JCI163669.
    PubMed     Abstract available
    
    
    October 2022
30. SUNGUR CM, Wang Q, Ozanturk AN, Gao H, et al
    Human natural killer cells confer protection against HIV-1 infection in humanized mice.
    J Clin Invest. 2022 Oct 25. pii: 162694. doi: 10.1172/JCI162694.
    PubMed     Abstract available
    
    
    
31. SHI G, Chiramel AI, Li T, Lai KK, et al
    Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2.
    J Clin Invest. 2022 Oct 20. pii: 160766. doi: 10.1172/JCI160766.
    PubMed     Abstract available
    
    
    August 2022
32. FOX DA
    Immunodeficiency and autoimmunity: companions not opposites.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    July 2022
33. GRUDDA T, Hwang HS, Taddese M, Quinn J, et al
    Integrated hepatitis B virus DNA maintains surface antigen production during antivirals.
    J Clin Invest. 2022 Jul 7. pii: 161818. doi: 10.1172/JCI161818.
    PubMed     Abstract available
    
    
    June 2022
34. TAKATA H, Trautmann L
    Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    May 2022
35. BALLE C, Armistead B, Kiravu A, Song X, et al
    Factors influencing maternal microchimerism throughout infancy and its impact on infant T cell immunity.
    J Clin Invest. 2022 May 12. pii: 148826. doi: 10.1172/JCI148826.
    PubMed     Abstract available
    
    
    April 2022
36. FALCINELLI SD, Peterson JJ, Turner AW, Irlbeck D, et al
    Combined noncanonical NF-kappaB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
37. PERDOMO-CELIS F, Passaes C, Monceaux V, Volant S, et al
    Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control.
    J Clin Invest. 2022 Apr 5. pii: 157549. doi: 10.1172/JCI157549.
    PubMed     Abstract available
    
    
    
38. LEYRE L, Jones RB
    Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity.
    J Clin Invest. 2022;132:1-4.
    PubMed     Abstract available
    
    
    March 2022
39. VARCO-MERTH BD, Brantley W, Marenco A, Duell DD, et al
    Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.
    J Clin Invest. 2022 Mar 22. pii: 156063. doi: 10.1172/JCI156063.
    PubMed     Abstract available
    
    
    
40. FERRARI B, Da Silva AC, Liu KH, Saidakova EV, et al
    Gut-derived bacterial toxins impair memory CD4 T-cell mitochondrialfunction in HIV-1infection.
    J Clin Invest. 2022 Mar 22. pii: 149571. doi: 10.1172/JCI149571.
    PubMed     Abstract available
    
    
    
41. HARPER J, Ribeiro SP, Chan CN, Aid M, et al
    Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy.
    J Clin Invest. 2022 Mar 1. pii: 155251. doi: 10.1172/JCI155251.
    PubMed     Abstract available
    
    
    February 2022
42. DUETTE G, Hiener B, Morgan H, Mazur FG, et al
    The HIV-1 proviral landscape reveals Nef contributes to HIV-1 persistence in effector memory CD4+ T-cells.
    J Clin Invest. 2022 Feb 8. pii: 154422. doi: 10.1172/JCI154422.
    PubMed     Abstract available
    
    
    
43. ARMSTRONG E, Hemmerling A, Miller S, Burke KE, et al
    Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli.
    J Clin Invest. 2022 Feb 3. pii: 152930. doi: 10.1172/JCI152930.
    PubMed     Abstract available
    
    
    December 2021
44. SHARAN R, Ganatra SR, Bucsan AN, Cole J, et al
    Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a tuberculosis/simian immunodeficiency virus coinfection model.
    J Clin Invest. 2021 Dec 2. pii: 153090. doi: 10.1172/JCI153090.
    PubMed     Abstract available
    
    
    
45. CAMPION SL, Brenna E, Thomson E, Fischer W, et al
    Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    November 2021
46. SCULLY EP, Bryson BD
    Unlocking the complexity of HIV and Mycobacterium tuberculosis coinfection.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
47. MITCHELL JL, Pollara J, Dietze K, Edwards RW, et al
    Anti-HIV antibody development up to one year after antiretroviral therapy initiation in acute HIV infection.
    J Clin Invest. 2021 Nov 11. pii: 150937. doi: 10.1172/JCI150937.
    PubMed     Abstract available
    
    
    October 2021
48. LI M, Garforth SJ, O'Connor KE, Su H, et al
    T-cell receptor-specific immunotherapeutics drive selective in vivo HIV and CMV-specific T-cell expansion in humanized mice.
    J Clin Invest. 2021 Oct 21. pii: 141051. doi: 10.1172/JCI141051.
    PubMed     Abstract available
    
    
    
49. PETERSON CW
    HIV-specific CAR T cells return to the clinic.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    September 2021
50. QUINN TC
    Forty years of AIDS: a retrospective and the way forward.
    J Clin Invest. 2021;131.
    PubMed    
    
    
    
51. DIAS J, Fabozzi G, March K, Asokan M, et al
    Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    August 2021
52. MENDEZ-LAGARES G, Chin N, Chang WLW, Lee J, et al
    Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.